01 Growing Adoption of Multi-Analyte and Third-Party Molecular Quality Controls The molecular quality control market is increasingly shifting toward multi-analyte and independent third-party controls that can support multiple molecular assays while providing laboratories with objective verification of testing performance. These controls are becoming more valuable as laboratories manage multiplex infectious disease panels, oncology assays, genetic testing, and other complex workflows that require consistent analytical performance across instruments and reagent batches. In 2026, market research identified independent controls as the leading product segment, while multi-analyte controls were among the fastest-growing categories as multiplex molecular testing expanded.
02 Increasing Integration of Automation and Digital Quality Management in Molecular Testing Molecular laboratories are increasingly integrating automated quality control workflows with laboratory information systems and digital monitoring platforms to track assay performance, identify deviations, and maintain traceability. This shift is moving quality assurance from periodic manual checks toward continuous monitoring, allowing laboratories to analyze quality trends across instruments, locations, operators, and testing batches. In 2026, industry research highlighted automation, digital quality management, and laboratory information systems as important developments supporting more standardized and efficient molecular testing workflows.
01 Expansion of Molecular Testing Applications Across Clinical and Research Settings Supports Market Growth Molecular testing is expanding across infectious disease diagnostics, oncology, genetic testing, precision medicine, and research applications, increasing the complexity and diversity of laboratory workflows. The broader use of PCR, next-generation sequencing, multiplex assays, and molecular biomarker testing is strengthening the need for reliable laboratory processes and performance verification, supporting the overall molecular quality control market.
01 High Costs and Regulatory Requirements Can Limit Adoption of Advanced Quality Controls Molecular quality control programs require recurring expenditure on control materials, validation procedures, proficiency testing, laboratory personnel, and documentation. Evolving regulatory requirements can further increase compliance costs as laboratories and manufacturers must demonstrate traceability, analytical performance, and consistent quality, creating greater financial pressure for smaller diagnostic facilities.
01 Expansion of Quality Control Solutions for Oncology and Genetic Testing Creates New Growth Opportunities The increasing use of molecular biomarkers in oncology, hereditary disease testing, and precision medicine is creating opportunities for specialized quality control materials designed for complex genetic and molecular assays. As laboratories expand testing for targeted biomarkers and sequencing-based diagnostics, demand is increasing for controls that can verify the performance of these assays and support reliable clinical interpretation.
01 Maintaining Control Material Stability and Compatibility Across Complex Testing Platforms Creates Challenges Molecular quality controls must accurately replicate relevant biological characteristics while remaining stable during storage, transportation, and repeated laboratory use. Differences among PCR, sequencing, multiplex, and other molecular platforms can also require application-specific controls, increasing development complexity and making it challenging to provide standardized materials that perform consistently across diverse diagnostic workflows.
November 2025 Bio-Rad Laboratories expanded its Exact Diagnostics molecular quality control portfolio with independent controls and verification materials for molecular diagnostic laboratories. The solutions support assay validation, lot-to-lot reproducibility, and routine quality monitoring.
October 2025 Microbiologics expanded its molecular quality control solutions for infectious disease testing and multiplex molecular assays. The portfolio supports laboratories in verifying assay performance and maintaining standardized diagnostic workflows.
August 2025 ZeptoMetrix advanced its NATtrol molecular control portfolio for molecular infectious disease testing. The expanded controls support nucleic acid amplification workflows and help laboratories assess molecular assay performance.
July 2025 SeraCare Life Sciences expanded its molecular quality control capabilities for next-generation sequencing and oncology testing workflows. The solutions support assay development, validation, and performance monitoring across advanced molecular laboratories.